BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-08-11

Last Posted Date: 2023-09-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 367

Registration Number: NCT02864251

Locations: 🇺🇸
Local Institution - 0033, Los Angeles, California, United States
🇺🇸
Torrance Memorial Physican Network, Redondo Beach, California, United States
🇺🇸
Baylor Scott and White Research Institute, Temple, Texas, United States

and more 48 locations

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Phase 1

Terminated

Conditions: Healthy Volunteers
Ulcerative Colitis

Interventions: Drug: BMS-986184
Drug: Placebo matching BMS-986184

First Posted Date: 2016-08-11

Last Posted Date: 2017-10-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT02864264

Locations: 🇲🇩
Local Institution, Chisinau, Moldova, Republic of

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Nivolumab

First Posted Date: 2016-08-05

Last Posted Date: 2021-12-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 66

Registration Number: NCT02857426

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States

and more 24 locations

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Completed

Conditions: Hodgkin's Disease

First Posted Date: 2016-08-05

Last Posted Date: 2021-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 290

Registration Number: NCT02856646

Locations: 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

Early Patient Access Treatment Use Protocol CA204-220

Conditions: Multiple Myeloma

First Posted Date: 2016-08-04

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02856438

Locations: 🇯🇵
Local Institution, Osaka-shi, Osaka, Japan

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Completed

Conditions: Encephalitis

Interventions: Biological: Nivolumab

First Posted Date: 2016-08-04

Last Posted Date: 2022-06-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 486

Registration Number: NCT02856451

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

Yervoy Pregnancy Surveillance Study

Withdrawn

Conditions: Melanoma

Interventions: Drug: Yervoy

First Posted Date: 2016-08-03

Last Posted Date: 2022-03-31

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02854488

Locations: 🇺🇸
UBC, Baltimore, Maryland, United States

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Completed

Conditions: Melanoma
Lung Cancer

First Posted Date: 2016-07-28

Last Posted Date: 2024-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1189

Registration Number: NCT02847728

Locations: 🇺🇸
Local Institution - 1901, Park Ridge, Illinois, United States
🇺🇸
Local Institution - 1906, Tupelo, Mississippi, United States
🇩🇪
Local Institution - 1430, Greifswald, Mecklenburg-Vorpommern, Germany

and more 91 locations

Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates

Completed

Conditions: Lung Cancer

First Posted Date: 2016-07-27

Last Posted Date: 2018-03-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 382

Registration Number: NCT02845089

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Phase 2

Terminated

Conditions: Sjögren's Syndrome

Interventions: Drug: BMS-986142
Drug: BMS-931699
Drug: Placebo

First Posted Date: 2016-07-26

Last Posted Date: 2018-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 45

Registration Number: NCT02843659

Locations: 🇺🇸
Arthritis And Osteoporosis Associates, Pa, Freehold, New Jersey, United States
🇺🇸
Acme Research, Llc, Orangeburg, South Carolina, United States
🇺🇸
West Tennessee Research Institute, Jackson, Tennessee, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy